Michael Richard Feldschuh
Known title: CEO & PresidentCIK: 0001589491
Michael Richard Feldschuh's purchase track record
How the stock did after each of Michael Richard Feldschuh's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 7 since May 24, 2023
Stock higher 6 months later
86%
3 months: 86%
Median 6-month return
+15.8%
3 months: +6.7%
Beat the S&P 500
71%
median +1.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/8/2026 | DXR | $9K | +15.5% | +15.8% | +15.0% |
| 4/4/2025 | DXR | $16K | +29.1% | +81.9% | +32.4% |
| 3/10/2025 | DXR | $26K | +19.4% | +47.2% | +15.7% |
| 3/19/2024 | DXR | $13K | +5.2% | +14.2% | +8.8% |
| 12/1/2023 | DXR | $6K | +0.5% | +11.6% | +14.9% |
| 11/9/2023 | DXR | $11K | +6.7% | +21.3% | +19.9% |
| 5/24/2023 | DXR | $20K | -1.1% | -18.2% | +10.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DXR | ▲ Buy | Grant | 30,000 | $0 | 6/23/2026 | View on chart |
| DXR | ▲ Buy | Open Market | 1,000 | $9K | 4/8/2026 | View on chart |
| DXR | ▲ Buy | Open Market | 2,063 | $16K | 4/4/2025 | View on chart |
| DXR | ▲ Buy | Open Market | 3,360 | $26K | 3/10/2025 | View on chart |
| DXR | ▲ Buy | Open Market | 45,000 | $0 | 12/6/2024 | View on chart |
| DXR | ▲ Buy | Open Market | 1,000 | $8K | 3/26/2024 | View on chart |
| DXR | ▲ Buy | Open Market | 647 | $5K | 3/19/2024 | View on chart |
| DXR | ▲ Buy | Open Market | 800 | $6K | 12/1/2023 | View on chart |
| DXR | ▲ Buy | Grant | 84 | $643 | 11/21/2023 | View on chart |
| DXR | ▲ Buy | Open Market | 1,001 | $8K | 11/10/2023 | View on chart |
| DXR | ▲ Buy | Open Market | 401 | $3K | 11/9/2023 | View on chart |
| DXR | ▲ Buy | Open Market | 2,000 | $20K | 5/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026
Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026. Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.